NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Bionic Sight, Inc.

Bionic Sight, Inc.

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.bionicsightllc.com/

Last Round

VC Round

Apr 1, 2025

Est. Valuation

$40M

Company Overview

Bionic Sight, Inc. is a biotechnology company developing optogenetic gene therapies and neuro-prosthetic devices to restore sight to patients with retinal degenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Computer Vision, Medical Devices, Drug Discovery

Business Model

B2B2C

Customer Profile

Revenue Share, Hardware + Subscription, Government Contracts

AI Layer

Non-AI

Keywords

optogenetic gene therapyvision restorationretinal degenerative diseaseretinitis pigmentosabionic eyeartificial visionoptogeneticsgene therapyneural codingmutation-agnostic therapyretinal prosthesiswearable medical deviceclinical-stage biotechRegenerative Medicine Advanced TherapyRMATgeographic atrophy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Bionic Sight, Inc. Comparables

Compare Bionic Sight, Inc. with similar companies based on industry and business-model similarity.

Bionic Sight, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ray Therapeutics
88%
Nanoscope Therapeutics Inc.
86%
SparingVision
83%

Bionic Sight, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundApr 1, 2025
VC RoundJan 24, 2017

Bionic Sight, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2025

    Raised capital from Partnership Fund for New York City.

  • Jan 24, 2017

    $2M round led by Beacon Therapeutics.

Bionic Sight, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Bionic Sight, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Bionic Sight, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Year Founded2012
Last FundingApr 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.